120 related articles for article (PubMed ID: 12453082)
1. Detection of unknown primary tumours in patients with cerebral metastases using whole-body 18F-flouorodeoxyglucose positron emission tomography.
Klee B; Law I; Højgaard L; Kosteljanetz M
Eur J Neurol; 2002 Nov; 9(6):657-62. PubMed ID: 12453082
[TBL] [Abstract][Full Text] [Related]
2. Whole-body [18F]FDG PET in the management of metastatic brain tumours.
Kim DG; Kim CY; Paek SH; Lee DS; Chung JK; Jung HW; Cho BK
Acta Neurochir (Wien); 1998; 140(7):665-73; discussion 673-4. PubMed ID: 9781280
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors.
Jeong HJ; Chung JK; Kim YK; Kim CY; Kim DG; Jeong JM; Lee DS; Jung HW; Lee MC
J Nucl Med; 2002 Nov; 43(11):1432-7. PubMed ID: 12411544
[TBL] [Abstract][Full Text] [Related]
4. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome).
Alberini JL; Belhocine T; Hustinx R; Daenen F; Rigo P
Nucl Med Commun; 2003 Oct; 24(10):1081-6. PubMed ID: 14508164
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).
Lassen U; Daugaard G; Eigtved A; Damgaard K; Friberg L
Eur J Cancer; 1999 Jul; 35(7):1076-82. PubMed ID: 10533451
[TBL] [Abstract][Full Text] [Related]
6. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of
Wolpert F; Weller M; Berghoff AS; Rushing E; Füreder LM; Petyt G; Leske H; Andratschke N; Regli L; Neidert MC; Stupp R; Stahel R; Dummer R; Frauenfelder T; Roth P; Reyns N; Kaufmann PA; Preusser M; Le Rhun E
Eur J Cancer; 2018 Jun; 96():64-72. PubMed ID: 29677642
[TBL] [Abstract][Full Text] [Related]
8. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study.
Johansen J; Eigtved A; Buchwald C; Theilgaard SA; Hansen HS
Laryngoscope; 2002 Nov; 112(11):2009-14. PubMed ID: 12439171
[TBL] [Abstract][Full Text] [Related]
9. [The role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases].
Fülöp M; Kásler M; Remenár E; Lengyel Z; Borbély K
Magy Onkol; 2012 May; 56(2):84-92. PubMed ID: 22629545
[TBL] [Abstract][Full Text] [Related]
10. Detection of unknown occult primary tumors using positron emission tomography.
Kole AC; Nieweg OE; Pruim J; Hoekstra HJ; Koops HS; Roodenburg JL; Vaalburg W; Vermey A
Cancer; 1998 Mar; 82(6):1160-6. PubMed ID: 9506364
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dissemination studies with FDG whole-body positron emission tomography in patients with suspected metastatic tumours of brain and spine.
Go KG; Pruim J; Que TH; Vaalburg W; Haaxma-Reiche H
Acta Neurochir (Wien); 2000; 142(6):627-31. PubMed ID: 10949436
[TBL] [Abstract][Full Text] [Related]
12. [Utility of PET-18FDG in primary tumor site in a patient with cerebral metastases].
Suárez Fernández JP; Serna Macías JA; Domínguez Grande ML; Liaño H; Pozo MA; Maldonado Suárez A
Rev Esp Med Nucl; 2005; 24(4):253. PubMed ID: 16122410
[No Abstract] [Full Text] [Related]
13. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
14. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
[TBL] [Abstract][Full Text] [Related]
15. In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET.
Joshi U; van der Hoeven JJ; Comans EF; Herder GJ; Teule GJ; Hoekstra OS
Br J Radiol; 2004 Dec; 77(924):1000-6. PubMed ID: 15569641
[TBL] [Abstract][Full Text] [Related]
16. FDG PET detection of unknown primary tumors.
Bohuslavizki KH; Klutmann S; Kröger S; Sonnemann U; Buchert R; Werner JA; Mester J; Clausen M
J Nucl Med; 2000 May; 41(5):816-22. PubMed ID: 10809197
[TBL] [Abstract][Full Text] [Related]
17. Detection of unknown primary tumor in patients presented with brain metastasis by F-18 fluorodeoxyglucose positron emission tomography/computed tomography.
Koç ZP; Kara PÖ; Dağtekin A
CNS Oncol; 2018 Apr; 7(2):CNS12. PubMed ID: 29708403
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.
Dietlein M; Krug B; Groth W; Smolarz K; Scheidhauer K; Psaras T; Stützer H; Lackner K; Schicha H
Nucl Med Commun; 1999 Mar; 20(3):255-61. PubMed ID: 10093075
[TBL] [Abstract][Full Text] [Related]
19. Value of fused positron emission tomography CT in detecting primaries in patients with primary unknown cervical lymph node metastasis.
Chen YH; Yang XM; Li SS; Wang YH; He JJ; Yang YD; Wang S; Liu JJ; Zhang XL
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):66-74. PubMed ID: 22339748
[TBL] [Abstract][Full Text] [Related]
20. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
